MiR-101-3p can significantly inactivate the PI3K/AKT pathway; inhibit the expression of Bcl-2 and MMP-9; and suppress the proliferation, migration, and invasion of NSCLC cells by directly binding to MALAT1 (53). Here, BCL2 is linked to non-small cell lung carcinoma.